Display options
Cite
Witzel TC, Wright T, McCabe L, et al. Impact and acceptability of HIV self-testing for trans men and trans women: A mixed-methods subgroup analysis of the SELPHI randomised controlled trial and process evaluation in England and Wales. EClinicalMedicine. 2021;32:100700doi: 10.1016/j.eclinm.2020.100700.
Witzel, T. C., Wright, T., McCabe, L., Gabriel, M. M., Wolton, A., Gafos, M., Ward, D., Lampe, F. C., Phillips, A. N., Trevelion, R., Collaco-Moraes, Y., Harbottle, J., Speakman, A., Bonell, C., Dunn, D. D., McCormack, S., Burns, F. M., Weatherburn, P., & Rodger, A. J. (2021). Impact and acceptability of HIV self-testing for trans men and trans women: A mixed-methods subgroup analysis of the SELPHI randomised controlled trial and process evaluation in England and Wales. EClinicalMedicine, 32100700. https://doi.org/10.1016/j.eclinm.2020.100700
Witzel, T Charles, et al. "Impact and acceptability of HIV self-testing for trans men and trans women: A mixed-methods subgroup analysis of the SELPHI randomised controlled trial and process evaluation in England and Wales." EClinicalMedicine vol. 32 (2021): 100700. doi: https://doi.org/10.1016/j.eclinm.2020.100700
Witzel TC, Wright T, McCabe L, Gabriel MM, Wolton A, Gafos M, Ward D, Lampe FC, Phillips AN, Trevelion R, Collaco-Moraes Y, Harbottle J, Speakman A, Bonell C, Dunn DD, McCormack S, Burns FM, Weatherburn P, Rodger AJ. Impact and acceptability of HIV self-testing for trans men and trans women: A mixed-methods subgroup analysis of the SELPHI randomised controlled trial and process evaluation in England and Wales. EClinicalMedicine. 2021 Feb 11;32:100700. doi: 10.1016/j.eclinm.2020.100700. eCollection 2021 Feb. PMID: 33681732; PMCID: PMC7910695.
Copy Download .nbib Format: NLM
Share it on

EClinicalMedicine. 2021 Feb 11;32:100700. doi: 10.1016/j.eclinm.2020.100700. eCollection 2021 Feb.

Impact and acceptability of HIV self-testing for trans men and trans women: A mixed-methods subgroup analysis of the SELPHI randomised controlled trial and process evaluation in England and Wales.

EClinicalMedicine

T Charles Witzel, Talen Wright, Leanne McCabe, Michelle M Gabriel, Aedan Wolton, Mitzy Gafos, Denise Ward, Fiona C Lampe, Andrew N Phillips, Roy Trevelion, Yolanda Collaco-Moraes, Justin Harbottle, Andrew Speakman, Chris Bonell, David D Dunn, Sheena McCormack, Fiona M Burns, Peter Weatherburn, Alison J Rodger

Affiliations

  1. Department of Public Health, Environments and Society, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SH, United Kingdom.
  2. Medical Research Council Clinical Trials Unit at University College London, 90 High Holborn, London WC1V 6LJ, United Kingdom.
  3. 56T, Chelsea and Westminster NHS Hospital Foundation Trust, 56 Dean Street, London W1D 4PR, United Kingdom.
  4. Department of Global Health and Development, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SH, United Kingdom.
  5. Institute for Global Health, University College London, Royal Free Hospital, Rowland Hill Street, London NW3 2PF, United Kingdom.
  6. HIV i-base, 107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ, United Kingdom.
  7. SH:24, 35a Westminster Bridge Road, South Bank, London SE1 7JB, United Kingdom.

PMID: 33681732 PMCID: PMC7910695 DOI: 10.1016/j.eclinm.2020.100700

Abstract

BACKGROUND: Globally, trans people are disproportionately affected by HIV, but research on strategies to increase testing are limited. SELPHI is a randomised-controlled-trial (RCT) of 10,135

METHODS: SELPHI recruited using social networking and trans focused social media. Participants were randomised 60/40 to baseline HIVST (Biosure™) (BT) vs no baseline HIVST (nBT); and at 3-months (if completed the survey and reported recent CAI) 50/50 to 3-monthly HIVST (RT) vs no repeat HIVST (nRT). Outcomes were self-reported through online surveys. We conducted a qualitative study of semi-structured peer-led participant interviews (

FINDINGS: SELPHI recruited and randomised 118 trans men and trans women (94 trans men, 24 trans women), of whom 20 (16 trans men, 4 trans women) underwent the second randomisation. Median age at baseline was 29 (IQR: 22, 37), 79% were white, 79% were UK born, 37% had degree level education, and 31% had never tested for HIV. 62% (

INTERPRETATION: HIVST significantly increased testing uptake and frequency in trans men and trans people overall, although recruitment and retention of trans women was low. HIVST acceptability was high and indicates easy access to this novel technology may increase HIV testing access for this key population.

© 2021 The Authors.

Keywords: Europe; HIV self-testing; New prevention technologies; Process evaluation; Randomised controlled trial; Trans men; Trans women; UK

Conflict of interest statement

Prof. Rodger reports grants from NIHR, during the conduct of the study; Prof. Phillips reports grants from NIHR, during the conduct of the study; Prof. Bonell reports grants from NIHR, during the cond

References

  1. J Int AIDS Soc. 2016 Jul 17;19(3 Suppl 2):21193 - PubMed
  2. Glob Public Health. 2016 Aug-Sep;11(7-8):1060-75 - PubMed
  3. Int J STD AIDS. 2017 Feb;28(2):133-137 - PubMed
  4. AIDS Behav. 2014 Jul;18 Suppl 4:S391-5 - PubMed
  5. J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):e89-e96 - PubMed
  6. AIDS Behav. 2020 Feb;24(2):506-515 - PubMed
  7. Curr Opin Infect Dis. 2017 Feb;30(1):50-57 - PubMed
  8. AIDS Care. 2017 Aug;29(8):990-995 - PubMed
  9. AIDS Behav. 2015 Nov;19(11):1949-65 - PubMed
  10. Transgend Health. 2018 Dec 28;3(1):239-250 - PubMed
  11. AIDS Behav. 2016 Apr;20(4):928-38 - PubMed
  12. Lancet. 2015 Jan 17;385(9964):274-86 - PubMed
  13. AIDS Patient Care STDS. 2018 Sep;32(9):360-367 - PubMed
  14. Int J Environ Res Public Health. 2020 Jan 10;17(2): - PubMed
  15. J Assoc Nurses AIDS Care. 2009 Sep-Oct;20(5):348-61 - PubMed
  16. Lancet. 2016 Jul 23;388(10042):412-436 - PubMed
  17. PLoS Med. 2018 Aug 28;15(8):e1002645 - PubMed
  18. BMJ Sex Reprod Health. 2020 Apr;46(2):116-125 - PubMed
  19. J Int AIDS Soc. 2016 Jul 17;19(3 Suppl 2):20779 - PubMed
  20. BMC Infect Dis. 2018 Oct 23;18(1):531 - PubMed
  21. J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):505-512 - PubMed
  22. BMC Infect Dis. 2019 Aug 8;19(1):699 - PubMed
  23. PLoS One. 2016 Sep 09;11(9):e0162713 - PubMed
  24. HIV Med. 2020 Mar;21(3):189-197 - PubMed
  25. BMC Med. 2020 Dec 3;18(1):381 - PubMed
  26. Lancet Infect Dis. 2013 Mar;13(3):214-22 - PubMed
  27. Int J Transgend. 2015;16(4):209-221 - PubMed
  28. Lancet. 2016 Jul 23;388(10042):390-400 - PubMed
  29. Sex Transm Infect. 2018 Aug;94(5):318-319 - PubMed
  30. J Am Acad Nurse Pract. 2011 Apr;23(4):175-82 - PubMed
  31. HIV Med. 2020 Oct;21(9):588-598 - PubMed

Publication Types

Grant support